You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 12, 2025

Patent: 9,677,062


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,677,062
Title:Hyaluronidase and factor VIII compositions
Abstract: Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP\'s), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided.
Inventor(s): Bookbinder; Louis H. (San Diego, CA), Kundu; Anirban (San Diego, CA), Frost; Gregory I. (Del Mar, CA)
Assignee: Halozyme, Inc. (San Diego, CA)
Application Number:13/374,500
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

United States Patent 9,677,062: A Comprehensive Analysis

Introduction

United States Patent 9,677,062, titled "Hyaluronidase and factor VIII compositions," is a significant patent that delves into the development and application of soluble neutral active Hyaluronidase Glycoproteins (sHASEGP) and their therapeutic uses. This analysis will explore the key aspects of the patent, including its claims, the patent landscape, and the implications for therapeutic applications.

Background of the Patent

The patent, filed as US13/374,500, pertains to the invention of sHASEGP, methods for their manufacture, and their use in facilitating the administration of other molecules. Hyaluronidase is an enzyme that breaks down hyaluronic acid, a key component of the extracellular matrix, thereby enhancing the diffusion of injected molecules[1].

Claims of the Patent

The patent includes several claims that are crucial for understanding its scope and applicability:

Composition Claims

  • The patent claims compositions that include sHASEGP and other therapeutic molecules, such as factor VIII, which is used in the treatment of hemophilia A[1].

Method Claims

  • It includes methods for the manufacture of sHASEGP, involving chemical modifications and expression plasmids[1].

Therapeutic Claims

  • The patent claims therapeutic methods using sHASEGP to modify glycosaminoglycans and to increase the diffusion of injected molecules less than 200 nanometers in diameter[1].

Patent Landscape

Prior Art

  • The patent application process involved a thorough review of prior art to ensure the novelty, non-obviousness, and usefulness of the claimed inventions. The examiner's review and the applicant's responses are documented in the patent's file wrapper, which provides valuable insights into the patentability of the claims[4].

Competitive Landscape

  • The use of hyaluronidase in therapeutic applications is not new, but the specific compositions and methods claimed in this patent differentiate it from existing technologies. Analyzing the file wrapper and other related patents helps in understanding the competitive landscape and potential challenges or opportunities[4].

Legal and Regulatory Aspects

Patentability

  • The patentability of the claims was evaluated based on the conditions of novelty, non-obviousness, and usefulness. The examiner's determination and the applicant's arguments during the prosecution process are critical in establishing the patent's validity[4].

Patent Eligibility

  • The patent's claims must also pass the test of patent eligibility under 35 U.S.C. § 101, ensuring they are not directed to abstract ideas or natural phenomena. The Alice two-step inquiry, as seen in other patent cases, would be applicable to determine if the claims are patent-eligible[2].

Therapeutic Applications

Enhancing Diffusion

  • The use of sHASEGP to increase the diffusion of injected molecules is a significant therapeutic application. This can improve the efficacy of treatments by ensuring that therapeutic molecules reach their target sites more effectively[1].

Treatment of Diseases

  • The patent highlights the therapeutic modification of glycosaminoglycans, which is crucial in the treatment of various diseases. Understanding the specific diseases targeted and the mechanisms involved is essential for appreciating the patent's value[1].

Industry Impact

Market Potential

  • The development of sHASEGP and their therapeutic applications has significant market potential. It can revolutionize the treatment of diseases by enhancing drug delivery and efficacy.

Competitive Advantage

  • Companies holding such patents can gain a competitive advantage in the pharmaceutical and biotechnology sectors. The ability to improve drug delivery systems can be a key differentiator in a highly competitive market.

Challenges and Limitations

Regulatory Hurdles

  • The patent faces regulatory hurdles, including the need to comply with FDA regulations and to pass clinical trials to prove safety and efficacy.

Intellectual Property Disputes

  • The patent landscape is complex, and disputes over patent infringement or validity can arise. Proper inventorship and the absence of deceptive intent are crucial to maintaining the patent's enforceability[5].

Key Takeaways

  • Innovative Composition: The patent introduces novel compositions involving sHASEGP, which enhance the diffusion of therapeutic molecules.
  • Therapeutic Applications: The patent has significant therapeutic applications, particularly in the treatment of diseases by modifying glycosaminoglycans.
  • Regulatory Compliance: The patent must comply with regulatory requirements, including patentability and patent eligibility tests.
  • Market Potential: The development has substantial market potential, offering a competitive advantage in drug delivery systems.

FAQs

Q: What is the primary focus of United States Patent 9,677,062?

A: The primary focus is on the development and therapeutic use of soluble neutral active Hyaluronidase Glycoproteins (sHASEGP).

Q: How do sHASEGP enhance therapeutic treatments?

A: sHASEGP enhance therapeutic treatments by increasing the diffusion of injected molecules, making them more effective in reaching their target sites.

Q: What are the key claims of the patent?

A: The patent includes claims related to the composition of sHASEGP, methods for their manufacture, and therapeutic methods using these compositions.

Q: Why is the file wrapper important in patent analysis?

A: The file wrapper provides detailed context and insights into the patent application process, including arguments between the applicant and the examiner, which are crucial for understanding the patent's validity and scope[4].

Q: What are the potential regulatory challenges for this patent?

A: The patent must comply with FDA regulations, pass clinical trials, and meet patent eligibility criteria under 35 U.S.C. § 101 to ensure its validity and enforceability.

Sources

  1. US9677062B2 - Hyaluronidase and factor VIII compositions - Google Patents
  2. AI VISUALIZE, INC. v. NUANCE COMMUNICATIONS, INC. - CAFC
  3. Q3 in Review: US NPE Upswing Continues as UPC Comes Further into Focus - RPX Corporation
  4. Patent file wrappers as a tool for competitive intelligence - IP Checkups
  5. Determining Inventorship for US Patent Applications - Oregon State University

More… ↓

⤷  Subscribe

Details for Patent 9,677,062

ApplicantTradenameBiologic IngredientDosage FormBLAApproval DatePatent No.Expiredate
Bausch & Lomb Incorporated VITRASE hyaluronidase Injection 021640 May 05, 2004 9,677,062 2023-03-05
Bausch & Lomb Incorporated VITRASE hyaluronidase Injection 021640 December 02, 2004 9,677,062 2023-03-05
Amphastar Pharmaceuticals, Inc. AMPHADASE hyaluronidase Injection 021665 October 26, 2004 9,677,062 2023-03-05
Akorn, Inc. HYDASE hyaluronidase Injection 021716 October 25, 2005 9,677,062 2023-03-05
>Applicant>Tradename>Biologic Ingredient>Dosage Form>BLA>Approval Date>Patent No.>Expiredate
Showing 1 to 4 of 4 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.